We are live on ! Find out more
SCM

Sio Capital Management Portfolio holdings

AUM $604M
1-Year Est. Return 96.57%
This Fund
S&P 500
This Quarter Est. Return
-9.83%
1 Year Est. Return
+96.57%
3 Year Est. Return
+564.25%
5 Year Est. Return
+486.18%
10 Year Est. Return
+2,856.71%
AUM
$370M
AUM Growth
+$33.7M
Cap. Flow
+$5.67M
Cap. Flow %
1.54%
Top 10 Hldgs %
68.63%
Holding
64
New
13
Increased
12
Reduced
8
Closed
16
Avg Time Held Equity + Options
2.8 quarters
Top 10 Avg Time Held Equity + Options
1.2 quarters
Top 20 Avg Time Held Equity + Options
1.8 quarters
Avg Time Held Equity only
2.8 quarters
Top 10 Avg Time Held Equity only
1.1 quarters
Top 20 Avg Time Held Equity only
1.7 quarters

Top Buys

Rank Stock Value
1
TFX icon
Teleflex
TFX
+$16.2M
2
SNN icon
Smith & Nephew
SNN
+$14.5M
3
VXRT icon
Vaxart
VXRT
+$12.3M
4
ZBH icon
Zimmer Biomet
ZBH
+$9.56M
5
ABT icon
Abbott
ABT
+$9.49M

Top Sells

Rank Stock Value
1
GMED icon
Globus Medical
GMED
+$21.1M
2
CI icon
Cigna
CI
+$17M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$13.6M
4
MDT icon
Medtronic
MDT
+$9.15M
5
EMBC icon
Embecta
EMBC
+$7.77M

Sector Composition

Rank Sector Weight
1 Healthcare 69.35%
2 Miscellaneous 28.26%
3 Consumer Staples 2.39%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
INSM icon
1
PUT
Insmed
INSM
$21.1B
$91.3M 24.71%
1,362,700
– –
2023 Q4
2 quarters
LH icon
2
Labcorp
LH
$25.4B
$50M 13.54%
245,902
+20,000
+9% +$4.07M
2023 Q2
4 quarters
TFX icon
3
Teleflex
TFX
$5.27B
$23.4M 6.32%
111,078
+77,200
+228% +$16.2M
2023 Q3
3 quarters
ZBH icon
4
Zimmer Biomet
ZBH
$17.6B
$16.9M 4.56%
155,304
+81,125
+109% +$9.56M
2023 Q3
3 quarters
SNN icon
5
Smith & Nephew
SNN
$11.7B
$14.4M 3.89%
+579,619
New +$14.5M
2024 Q2
0 quarters
PCRX icon
6
PUT
Pacira BioSciences
PCRX
$1.45B
$13M 3.53%
455,500
+343,500
+307% +$9.78M
2024 Q1
1 quarter
OGN icon
7
Organon & Co
OGN
$3.62B
$12.6M 3.41%
608,096
+129,073
+27% +$2.57M
2024 Q1
1 quarter
GSK icon
8
GSK
GSK
$92.7B
$12M 3.25%
312,000
+48,555
+18% +$2.04M
2023 Q2
4 quarters
CRBP icon
9
Corbus Pharmaceuticals
CRBP
$92.5M
$10.2M 2.76%
+225,165
New +$9.47M
2024 Q2
0 quarters
VXRT icon
10
DELISTED
Vaxart
VXRT
$9.85M 2.67%
+14,764,991
New +$12.3M
2024 Q2
0 quarters
TYRA icon
11
Tyra Biosciences
TYRA
$1.28B
$9.6M 2.6%
600,294
+64,553
+12% +$1.11M
2024 Q1
1 quarter
ABT icon
12
Abbott
ABT
$178B
$9.3M 2.52%
+89,500
New +$9.49M
2024 Q2
0 quarters
CI icon
13
Cigna
CI
$74.7B
$8.85M 2.4%
26,786
-49,300
-65% -$17M
2020 Q3
15 quarters
KVUE icon
14
Kenvue
KVUE
$34.1B
$8.82M 2.39%
+485,000
New +$9.4M
2024 Q2
0 quarters
IRON icon
15
Disc Medicine
IRON
$2.17B
$8.65M 2.34%
+192,000
New +$6.52M
2024 Q2
0 quarters
ERAS icon
16
Erasca
ERAS
$5.17B
$6.78M 1.84%
2,874,536
+447,352
+18% +$965K
2024 Q1
1 quarter
BDSX icon
17
Biodesix
BDSX
$264M
$6.65M 1.8%
+217,393
New +$6.21M
2024 Q2
0 quarters
ATXS icon
18
DELISTED
Astria Therapeutics
ATXS
$4.64M 1.26%
510,267
+100,000
+24% +$976K
2024 Q1
1 quarter
ANIP icon
19
ANI Pharmaceuticals
ANIP
$1.63B
$4.57M 1.24%
71,740
-15,614
-18% -$1.01M
2024 Q1
1 quarter
BLCO icon
20
Bausch + Lomb
BLCO
$5.65B
$4.4M 1.19%
+302,710
New +$4.55M
2024 Q2
0 quarters
PMVP icon
21
PMV Pharmaceuticals
PMVP
$72.2M
$4.39M 1.19%
+2,708,408
New +$4.88M
2024 Q2
0 quarters
ZYME icon
22
Zymeworks
ZYME
$1.8B
$4.18M 1.13%
+491,128
New +$4.37M
2024 Q2
0 quarters
BBIO icon
23
BridgeBio Pharma
BBIO
$12.4B
$3.17M 0.86%
125,174
-78,000
-38% -$2.13M
2023 Q3
3 quarters
APGE icon
24
DELISTED
Apogee Therapeutics
APGE
$3.07M 0.83%
78,000
– –
2024 Q1
1 quarter
CNTX icon
25
Context Therapeutics
CNTX
$25.3M
$2.66M 0.72%
+1,328,352
New +$2.29M
2024 Q2
0 quarters
1
2 3

Similar funds

EFL
ERn Financial LLC Middleton, Wisconsin $604M AUM 19.83% 1-Year Est. Return
V
VeraBank Henderson, Texas $604M AUM 23.32% 1-Year Est. Return
MAM
Morse Asset Management Darien, Connecticut $604M AUM 72.61% 1-Year Est. Return
RCM
Requisite Capital Management Dallas, Texas $605M AUM 17.2% 1-Year Est. Return
AMG
Advisors Management Group La Crosse, Wisconsin $604M AUM 64.38% 1-Year Est. Return
VV
Verbena Value Westport, Connecticut $605M AUM
VCP
Varenne Capital Partners Paris, France $603M AUM 46.34% 1-Year Est. Return
EHI
Eagle Health Investments Greenwich, Connecticut $603M AUM 111.06% 1-Year Est. Return

Sio Capital Management's Q2 2024 Portfolio in Review

As of Q2 2024, Sio Capital Management held 64 positions worth $370M, up 10% from $336M the previous quarter. Its ten largest holdings account for 69% of the portfolio.

Sio Capital Management's Q2 2024 filing shows 13 new, 12 increased, 8 reduced and 16 closed positions. Its largest new stake was Smith & Nephew: 579,619 shares worth $14.4M. The largest sale was Globus Medical, an estimated $21.1M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 85% a quarter earlier, followed by Miscellaneous and Consumer Staples.

  • Sio Capital Management's largest Q2 2024 buy was Smith & Nephew: 579,619 shares worth $14.4M.
  • Sio Capital Management added most to Teleflex in Q2 2024, an estimated $16.2M increase.
  • Sio Capital Management's biggest Q2 2024 reduction was Cigna, cutting an estimated $17M.
  • Sio Capital Management fully exited Globus Medical in Q2 2024, selling an estimated $21.1M.
  • Sio Capital Management's ten largest holdings make up 69% of its $370M portfolio in Q2 2024.
  • Sio Capital Management opened 13 new positions and closed 16 in Q2 2024.
  • Sio Capital Management's portfolio value rose 10% quarter-over-quarter to $370M.

Based on Sio Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.